[HTML][HTML] Midkine expression by stem-like tumor cells drives persistence to mTOR inhibition and an immune-suppressive microenvironment

Y Tang, DJ Kwiatkowski, EP Henske - Nature communications, 2022 - nature.com
Nature communications, 2022nature.com
Abstract mTORC1 is hyperactive in multiple cancer types,. Here, we performed integrative
analysis of single cell transcriptomic profiling, paired T cell receptor (TCR) sequencing, and
spatial transcriptomic profiling on Tuberous Sclerosis Complex (TSC) associated tumors
with mTORC1 hyperactivity, and identified a stem-like tumor cell state (SLS) linked to T cell
dysfunction via tumor-modulated immunosuppressive macrophages. Rapamycin and its
derivatives (rapalogs) are the primary treatments for TSC tumors, and the stem-like tumor …
Abstract
mTORC1 is hyperactive in multiple cancer types,. Here, we performed integrative analysis of single cell transcriptomic profiling, paired T cell receptor (TCR) sequencing, and spatial transcriptomic profiling on Tuberous Sclerosis Complex (TSC) associated tumors with mTORC1 hyperactivity, and identified a stem-like tumor cell state (SLS) linked to T cell dysfunction via tumor-modulated immunosuppressive macrophages. Rapamycin and its derivatives (rapalogs) are the primary treatments for TSC tumors, and the stem-like tumor cells showed rapamycin resistance in vitro, reminiscent of the cytostatic effects of these drugs in patients. The pro-angiogenic factor midkine (MDK) was highly expressed by the SLS population, and associated with enrichment of endothelial cells in SLS-dominant samples. Inhibition of MDK showed synergistic benefit with rapamycin in reducing the growth of TSC cell lines in vitro and in vivo. In aggregate, this study suggests an autocrine rapamycin resistance mechanism and a paracrine tumor survival mechanism via immune suppression adopted by the stem-like state tumor cells with mTORC1 hyperactivity.
nature.com